Drug Profile
Research programme: tuberculosis therapies - Global Alliance for TB Drug Development
Alternative Names: NITD304; PA-824 analogues; Pretomanid analoguesLatest Information Update: 31 Aug 2017
Price :
$50
*
At a glance
- Originator Novartis Institute for Tropical Diseases
- Developer Global Alliance for TB Drug Development
- Class Amides; Indoles; Nitroimidazoles; Small molecules
- Mechanism of Action Membrane transport protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Tuberculosis
Most Recent Events
- 31 Aug 2017 Discontinued - Preclinical for Tuberculosis in USA (PO)
- 20 Aug 2014 Novartis Institute for Tropical Diseases grants Global Alliance for TB Drug Development an exclusive global license for all further development and distribution of the tuberculosis therapies programme
- 27 Jun 2012 Preclinical development is ongoing USA and Singapore